Biopharmaceutical industry leader with more than two decades of broad management experience, supported by nearly a decade of prior experience as a practicing physician. Inspired to re-join the industry after an early retirement to help address the ongoing healthcare disparities facing the sickle cell disease community, and led Global Blood Therapeutics, Inc. on its mission to develop therapies for this underserved patient population for more than nine years. Currently serving as the Chair of the Board of Directors for the Biotechnology Innovation Organization and on the Boards of Directors for Structure Therapeutics, Royalty Pharma and Seagen. Holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School; completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.My vision for the future of sickle cell disease diagnosis, treatment and management: https://www.youtube.com/watch?v=tzBpse3oapk